K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval ...

Evolving global expectations for CGT validation, comparability, and supply continuity elevate the need for operational and ...

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most ...

Mechanistically, HM17321 is a Ucn2 analog enabling a non-GLP-1 approach aimed at improving body composition by selectively reducing adiposity while preserving muscle mass and function. Preclinical ...

LaValle has worked with elite sports teams, military, and first responders, optimizing performance and recovery. He has authored 26 books, including Cracking the Metabolic Code, and over 200 articles.

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how ...

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...

Ying Huang, Ph.D., is the Chief Executive Officer and Board Director of K2 Therapeutics, and Strategic Advisor, APAC at MPM BioImpact. He brings over 9 years of experience in research and development ...

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner. President Donald Trump has chosen Heidi Overton, a White ...

Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's ...

From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...